QINGSONG HEALTH (02661) saw its shares rise close to 8% during the morning trading session. At the time of writing, the stock was up 7.05%, trading at HKD 56.2, with a turnover of HKD 30.23 million. The increase follows the company's recent announcement that its self-developed AI-powered evidence-based medicine agent, named "Zheng Yuanfang," has been officially integrated into the "Yilu Qingsong" service platform for doctors and medical professionals. This marks a product-level integration of the group's proprietary medical AI capabilities with its own physician service network. Public data shows that as of March 31, 2026, the "Yilu Qingsong" platform, empowered by "Zheng Yuanfang," had reached 69,615 medical professional users, representing a year-on-year increase of 46.4%. Among these users, 36,678 were associate chief physicians or higher, accounting for approximately 52.7% of the total and growing 42.7% year-on-year. The platform also had 3,672 ophthalmology professionals, a surge of 171.0% compared to the previous year. The company has established a three-tier AI framework consisting of the "Stellar Cloud Digital Base," the "Dr. GPT specialized medical large language model," and the "Zheng Yuanfang series of evidence-based medicine agents."